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Introduction
The hormones secreted in response to nutrient intake are essential for maintaining glucose homeostasis 
and development of  diabetes. Insulin secreted from pancreatic β cells in response to elevated blood glu-
cose acts on peripheral tissues to increase glucose uptake, while glucagon secreted from α cells counter-
acts low glucose levels by promoting gluconeogenesis and glycogenolysis in the liver (1).
The two incretin hormones, glucose-dependent insulinotropic peptide (GIP) and glucagon-like pep-
tide-1 (GLP-1), are released into the circulation by intestinal enteroendocrine cells (K and L cells, respec-
tively) in response to nutrient stimulation and act on β cells to increase insulin secretion. In addition 
to their insulinotropic activity both hormones exert a number of  other functions, such as promotion 
of  energy storage and bone formation. GIP acts via the GIP receptor (GIPR), which is expressed in 
numerous tissues, including pancreatic islets, fat, bone, and vascular endothelial cells. GLP-1 acts via the 
GLP-1 receptor and affects biological functions such as regulation of  food intake, stimulation of  insulin 
synthesis, inhibition of  glucagon secretion, and gastric emptying (2).
Several therapeutic agents for treatment of  type 2 diabetes (T2D) act by increasing GLP-1 action, i.e., 
GLP-1 receptor agonists or GLP-1 analogs and inhibitors of  the dipeptidyl peptidase–4 (DPP4) enzyme, 
which inactivates both GIP and GLP-1 within minutes after their secretion (3). Furthermore, long-term 
weight loss, improved glucose tolerance, and remission of  T2D following bariatric surgery are suggested to 
involve an exaggerated GLP-1 response (4).
Numerous GWAS have identified genetic variants that affect plasma concentration of  insulin (5–8), but 
such information is lacking for glucagon, GLP-1, and GIP concentrations.
The secretion of insulin and glucagon from the pancreas and the incretin hormones glucagon-like 
peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) from the gastrointestinal tract 
is essential for glucose homeostasis. Several novel treatment strategies for type 2 diabetes (T2D) 
mimic GLP-1 actions or inhibit incretin degradation (DPP4 inhibitors), but none is thus far aimed 
at increasing the secretion of endogenous incretins. In order to identify new potential therapeutic 
targets for treatment of T2D, we performed a meta-analysis of a GWAS and an exome-wide 
association study of circulating insulin, glucagon, GIP, and GLP-1 concentrations measured during 
an oral glucose tolerance test in up to 7,828 individuals. We identified 6 genome-wide significant 
functional loci associated with plasma incretin concentrations in or near the SLC5A1 (encoding 
SGLT1), GIPR, ABO, GLP2R, F13A1, and HOXD1 genes and studied the effect of these variants on 
mRNA expression in pancreatic islet and on metabolic phenotypes. Immunohistochemistry showed 
expression of GIPR, ABO, and HOXD1 in human enteroendocrine cells and expression of ABO in 
pancreatic islets, supporting a role in hormone secretion. This study thus provides candidate genes 
and insight into mechanisms by which secretion and breakdown of GIP and GLP-1 are regulated.
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To identify potential novel targets to therapeutically manipulate circulating levels of  these hormones 
we performed a GWAS of  circulating plasma levels of  glucagon, GIP, and GLP-1 as well as insulin (as 
positive control), measured during an oral glucose tolerance test (OGTT) and meta-analyzed with data 
from an exome-wide study of  the same phenotypes in an independent cohort. Thereby, we identified 6 loci 
associated with incretin levels at genome-wide significance in or near the solute carrier family 5 member 1 
(SLC5A1), gastric inhibitory polypeptide receptor (GIPR), ABO blood group (ABO), glucagon-like peptide 2 
receptor (GLP2R), coagulation factor XIII A chain (F13A1), and homeobox D1 (HOXD1) genes.
Results
We performed a GWAS of  circulating levels of  insulin, glucagon, GIP, and GLP-1 measured at 0 and 2 
hours of  an OGTT (plus 30 minutes for insulin) in a Swedish population-based cohort of  3,344 individ-
uals (Malmö Diet and Cancer study [MDC]) genotyped using the Illumina Infinium OmniExpressEx-
ome v1.0 B array. The results were meta-analyzed with data from 4,905 Finnish individuals from the 
Prevalence, Prediction and Prevention of  Diabetes Botnia study (PPP-Botnia) genotyped with the Illu-
mina Infinium Exome v1.0 Beadchip. After quality control (QC), 81,396 exome SNPs were present in 
analysis of  both cohorts. Manhattan and QQ plots are presented in Supplemental Figures 1 and 2 (sup-
plemental material available online with this article; https://doi.org/10.1172/jci.insight.93306DS1). 
The significant associations were used to examine other potential phenotypic associations and the effect 
on gene expression in target tissues.
Heritability of  circulating hormone concentrations. The “narrow-sense heritability” of  hormone concentra-
tions during OGTT, estimated as total variance explained by the genotyped SNPs, i.e., the proportion of  
variation in the phenotype that can be attributed to effects of  the genotyped SNPs, was calculated in the 
MDC cohort using Genome-Wide Complex Trait Analysis (GCTA) (9). The heritability of  insulin ranged 
from 11% for fasting to 23% for circulating insulin at 30 minutes of  the OTGG (30-minute insulin). Fasting 
GIP, 2-hour GIP, and 2-hour GLP-1 showed heritabilities of  approximately 15%, and fasting glucagon 
showed a heritability of  around 20% (Supplemental Table 1). Only the heritabilities of  30-minute insulin 
and fasting glucagon were significantly higher than 0.
Genetic variants associated with insulin concentration. As several studies have reported genetic variants asso-
ciated with insulin concentrations in nondiabetic individuals, we searched for similar associations in our 
cohorts as positive controls. The strongest association with fasting insulin was seen for the rs2943641 SNP 
(P = 2.4 × 10–7) near the insulin receptor substrate 1 (IRS1) gene that has previously been shown to be 
associated with T2D and insulin resistance (10). This locus was also most strongly associated with 2-hour 
insulin (P = 1.35 × 10–5). As previously reported (5), variants in GIPR were associated with reduced insulin 
concentration at 30 minutes of  an OGTT by 8% per allele (Table 1 and Supplemental Figure 3A). The sec-
ond strongest association was seen for rs5015480 (P = 4.9 × 10–7) in a previously reported T2D locus near 
the hematopoietically expressed homeobox (HHEX) gene (11). SNPs at least suggestively associated (P < 
10–5) with insulin are presented in Supplemental Table 2.
Figure 1. GIP receptor expression in enteroendocrine cells. Human intestinal sections. (A) Colonal sections double 
immunostained for glucose-dependent insulinotropic peptide receptor (GIPR) and glucagon-like peptide-1 (GLP-1). (B) 
Jejunal sections double immunostained for GIPR and glucose-dependent insulinotropic peptide (GIP). Scale bar: 10 μm.
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Genetic variants associated with glucagon concentrations. The strongest association of  fasting glucagon concen-
trations was seen for an intronic SNP, rs7102710, in the gene encoding spondin 1 (SPON1, P = 8.2 × 10–7). The 
SPON1 gene was observed to be highly expressed in pancreatic islets from 191 human cadaver donors (mRNA 
higher than 73.3% of all genes), and the expression correlated positively with hemoglobin A1c (HbA1c) levels 
(n = 116, r2 = 0.13, P = 5.2 × 10–5). However, rs7102710 was not an expression QTL (eQTL) for any gene 
within 1 Mb (P > 0.01) in the pancreatic islets. All SNPs significantly or suggestively associated (P < 10–5) with 
glucagon levels are presented in Supplemental Table 2.
Genetic variants associated with GLP-1 concentration. We observed a strong association with GLP-1 concen-
tration after OGTT for 2 missense variants in SLC5A1: rs17683011 (Asn51Ser, P = 4.2 × 10–8) and rs17683430 
(Ala411Thr, P = 5.2 × 10–8). These 2 variants are in complete linkage disequilibrium (LD) (r2 = 1, D′ = 1) and 
thus represent the same locus. Each G allele of rs17683011 increased the 2-hour GLP-1 concentration by 9.1% 
(P = 4.2 × 10–8). SLC5A1 encodes the sodium-dependent glucose transporter 1 (SGLT1), the main mediator 
Table 1. Genome-wide significant SNPs in MDC, PPP-Botnia, and meta-analysis
MDC PPP-Botnia Meta-analysis
Candidate 
gene
Chr. Position 
(bp)
SNP EA/
NEA
EAF n β SE P n β SE P n β SE P
Fasting 
GIPA
GLP2R 17 9792768 rs17681684 A/G 0.33 3,120  0.050 0.013 0.00019 4,706  0.059 0.012 1.6 × 
10–6
7,826  0.055 0.009 1.4 × 10–9
GIPR 19 46181392 rs1800437 C/G 0.26 3,119 –0.070 0.015 5.6 × 
10–7
4,706 –0.079 0.013 1.5 × 10–9 7,825 –0.076 0.010 4.1 × 
10–15
GIPR 19 46202172 rs2287019 T/C 0.23 3,122 –0.064 0.015 2.1 × 10–5 4,706 –0.068 0.013 4.4 × 
10–7
7,828 –0.066 0.010 4.0 × 
10–11
2-h GIPA
HOXD1 2 177054181 rs150112597 C/G 0.0055 2,759 –0.24 0.085 0.0056 4,684 –0.30 0.061 6.9 × 
10–6
7,443 –0.28 0.049 1.6 × 
10–8
F13A1 6 6331873 rs927332 T/C 0.55 2,758  0.028 0.012 0.014 4,684  0.048 0.0096 4.1 × 10–6 7,442  0.040 0.007 4.1 × 10–8
ABO 9 136155000 rs635634 T/C 0.20 2,762 –0.074 0.014 2.9 × 
10–7
4,684 –0.067 0.012 8.5 × 
10–7
7,446 –0.070 0.009 7.4 × 
10–14
ABO 9 136149399 rs507666 A/G 0.19 2,766 –0.074 0.014 2.7 × 10–7 4,684 –0.066 0.012 1.0 × 
10–6
7,450 –0.069 0.009 8.9 × 
10–14
ABO 9 136153875 rs651007 T/C 0.21 2,765 –0.059 0.014 2.0 × 
10–5
4,684 –0.066 0.012 5.5 × 
10–7
7,449 –0.063 0.009 2.8 × 
10–12
ABO 9 136154168 rs579459 C/T 0.21 2,766 –0.058 0.014 2.8 × 
10–5
4,684 –0.066 0.012 4.7 × 
10–7
7,450 –0.062 0.009 3.4 × 
10–12
GIPR 19 46181392 rs1800437 C/G 0.26 2,764 –0.073 0.014 2.7 × 10–7 4,684 –0.072 0.011 8.9 × 
10–10
7,448 –0.072 0.009 1.6 × 
10–17
GIPR 19 46202172 rs2287019 T/C 0.24 2,766 –0.069 0.015 2.3 × 
10–6
4,684 –0.064 0.011 9.5 × 
10–8
7,450 –0.066 0.009 4.0 × 
10–14
SLC5A1 22 32487700 rs17683430 A/G 0.074 2,766  0.078 0.021 2.1 × 10–4 4,684  0.16 0.019 4.7 × 
10–14
7,450  0.12 0.014 3.0 × 
10–18
SLC5A1 22 32445946 rs17683011 G/A 0.074 2,766  0.078 0.021 2.4 × 
10–4
4684  0.16 0.019 4.3 × 
10–14
7450  0.12 0.014 3.2 × 
10–18
2-h GLP-
1A
SLC5A1 22 32445946 rs17683011 G/A 0.079 2,876 0.095 0.020 2.1 × 10–6 973 0.084 0.030 0.0076 3,849 0.091 0.017 4.2 × 
10–8
30-min 
insulinA
GIPR 19 46181392 rs1800437 C/G 0.26 2,642 –0.097 0.019 2.0 × 
10–7
4,601 –0.073 0.014 8.5 × 
10–8
7,243 –0.081 0.011 1.4 × 
10–13
GIPR 19 46202172 rs2287019 T/C 0.24 2,644 –0.085 0.019 1.1 × 10–5 4,601 –0.064 0.014 4.9 × 
10–6
7,245 –0.071 0.011 3.3 × 
10–10
Partially overlapping association data for the GIPR locus has been published previously (5, 19). ALn-transformed before analysis. EA, effect allele; NEA, 
noneffect allele; EAF, effect allele frequency; SE, standard error of the β coefficient; GLP2R, glucagon-like peptide 2 receptor; GIP, glucose-dependent 
insulinotropic peptide; GIPR, GIP receptor.
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of glucose uptake in the gut, which has been shown to be expressed in the apical membrane of both K and L 
cells and to be essential for incretin secretion in both humans and animal models (12–16). All genome-wide 
significant associations are presented in Table 1 and Supplemental Figure 3.
Genetic variants associated with GIP concentrations. Two independent loci were significantly associated 
with fasting GIP concentration: GIPR and GLP2R (Table 1). All SNPs at least suggestively associated 
(P < 10–5) with GIP and GLP-1 are presented in Supplemental Table 3.
GIPR. The minor alleles of  rs1800437 and rs2287019 (P = 4.0 × 10–11) in the GIPR locus were associ-
ated with lower fasting (P = 4.1 × 10–15) and 2-hour (P = 1.6 × 10–17) GIP concentrations. The rs1800437 
SNP is in strong LD (r2 = 0.94, D′ = 1) with the rs10423928 variant that has previously been associated 
with GIP concentrations in the PPP-Botnia cohorts as well as with several diabetes-related phenotypes, 
including insulin secretion, BMI, and expression of  GIPR mRNA in islets (5, 17–19). The rs1800437 
and rs2287019 variants are also in relatively strong linkage equilibrium (r2 = 0.7, D′ = 1) with each other. 
Table 2. Association between genome-wide loci and other metabolic phenotypes in meta-analysis of MDC and PPP-Botnia
HOXD1 
(rs150112597-C)
F13A1  
(rs927332-T)
ABO  
(rs635634-T)
GLP2R 
(rs17681684-A)
GIPR  
(rs1800437-C)
SLC5A1 
(rs17683011-G)
Phenotype  n β ± SE P β ± SE P β ± SE P  n β ± SE P β ± SE P β ± SE P
Fasting GIP 7,828 –0.13 ± 
0.058
0.020 0.036 ± 
0.0084
2.5 × 10–5 –0.036 ± 
0.011
6.9 × 10–4 7,828 0.055 ± 
0.0090
1.4 × 10–9 –0.076 ± 
0.0097
4.1 × 
10–15
0.033 ± 
0.016
0.036
2-h GIP 7,450 –0.28 ± 
0.049
1.6 × 10–8 0.040 ± 
0.0074
4.1 × 10–8 –0.070 ± 
0.0093
7.4 × 10–14 7,450 0.0039 ± 
0.0079
0.62 –0.072 ± 
0.0085
1.6 × 
10–17
0.12 ± 
0.014
3.2 × 10–18
Fasting 
GLP-1
4,181 –0.0091 ± 
0.061
0.88 –0.00049 
± 0.0085
0.95 0.0012 ± 
0.011
0.91 4,181 0.0057 ± 
0.0092
0.54 0.028 ±  
0.010
0.0053 –0.0046 ± 
0.016
0.77
2-h GLP-1 3,849 0.10 ± 
0.066
0.13 0.0011 ± 
0.0089
0.91 –0.0084 
± 0.011
0.45 3,849 –0.035 ± 
0.0097
4.9 × 10–4 0.020 ±  
0.010
0.063 0.091 ± 
0.017
4.2 × 10–8
Fasting 
insulinA
7,785 –0.048 ± 
0.063
0.45 0.0034 ± 
0.0090
0.70 0.0047 ± 
0.011
0.68 7,785 0.0092 ± 
0.0096
0.34 –0.025 ± 
0.010
0.015 –0.0030 ± 
0.017
0.86
30-min 
insulinA
7,245 0.046 ± 
0.065
0.48 0.012 ± 
0.0096
0.22 –0.042 ± 
0.012
5.7 × 10–4 7,245 0.020 ± 
0.010
0.053 –0.081 ±  
0.011
1.4 × 
10–13
–0.018 ± 
0.018
0.33
2-h insulinA 7,349 –0.17 ± 
0.087
0.051 0.012 ± 
0.013
0.37 0.018 ± 
0.016
0.27 7,349 –0.0086 ± 
0.014
0.53 –0.038 ± 
0.015
0.011 0.0046 ± 
0.024
0.85
Fasting 
glucagon
6,683 –0.0097 ± 
0.030
0.74 –0.0023 ± 
0.0045
0.62 0.00033 ± 
0.0057
0.95 6,683 0.0055 ± 
0.0049
0.25 –0.00036 ± 
0.0052
0.95 0.0047 ± 
0.0086
0.60
2-h 
glucagon
6,242 0.0015 ± 
0.030
0.96 0.00055 ± 
0.0046
0.91 –0.0047 ± 
0.0058
0.42 6,242 –0.010 ± 
0.0050
0.041 –0.0048 ± 
0.0053
0.37 0.035 ± 
0.0089
7.3 × 10–5
Fasting 
glucoseA
7,316 –0.081 ± 
0.062
0.20 0.0028 ± 
0.0095
0.77 0.025 ± 
0.012
0.038 7,316 –0.022 ± 
0.010
0.028 –0.0077 ± 
0.011
0.48 –0.039 ± 
0.018
0.033
2-h glucoseA 7,736 –0.11 ± 
0.035
0.0024 0.0030 ± 
0.0053
0.56 0.021 ± 
0.0066
0.0014 7,736 –0.0016 ± 
0.0056
0.78 0.015 ± 
0.0060
0.011 –0.0049 ± 
0.010
0.62
BMI 8,201 –0.035 ± 
0.016
0.034 0.00034 
± 0.0024
0.89 0.0085 ± 
0.0031
0.0052 8,201 –0.00088 ± 
0.0026
0.73 –0.014 ± 
0.0028
6.0 × 
10–7
–0.0049 ± 
0.0046
0.29
CIRA,B 4,572 0.14 ±  
0.10
0.18 0.0002 ± 
0.016
0.99 –0.026 ± 
0.021
0.216 4,572 0.026 ± 
0.017
0.11 –0.053 
(0.018)
0.004 0.100 ± 
0.032
0.002
AOnly nondiabetic individuals included in analysis. BPPP-Botnia only. SE, standard error of the β coefficient; GIP, glucose-dependent insulinotropic peptide; 
GLP-1, glucagon-like peptide-1; CIR, corrected insulin response.
Table 3. Estimated ABO allele frequencies and association results for ABO alleles
ABO allele Frequency β(SE) fasting GIP P fasting GIP β(SE) 2-h GIP P 2-h GIP
O (Ref) 0.62 – – – –
A1 0.20 –0.045 (0.012) 1.0 × 10–4 –0.074 (0.011) 1.9 × 10–12
B 0.11 –0.015 (0.015) 0.33 –0.023 (0.013) 0.076
A2 0.08 –0.042 (0.017) 0.012 –0.024 (0.015) 0.10
GIP, glucose-dependent insulinotropic peptide; SE, standard error of the β coefficient; Ref, reference group.
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Analysis conditioned on rs1800437 showed no independent association for rs2287019 (P = 0.8), suggest-
ing that they represent the same locus. The minor C allele of  rs1800437 was also nominally associated 
with increased fasting (P = 5.3 × 10–3) but not 2-hour GLP-1 (Table 2). In accordance with previous 
publications, the same allele was associated with decreased fasting insulin (P = 0.015), 30-minute insulin 
secretion (P = 1.4 × 10–13), 2-hour insulin concentrations (P = 0.011), BMI (P = 6.0 × 10–7), and increased 
2-hour glucose levels (P = 0.011, Table 2) (5, 17). However, in contrast to previously published results, 
the locus was not an eQTL for the GIPR gene (Supplemental Table 4 and Supplemental Figure 4). We 
also analyzed GIPR expression in K and L cells by immunohistochemical staining of  human colon and 
jejunum specimens and observed that the GIPR was expressed in subsets of  both K and L cells (Figure 1).
GLP2R. The second locus associated with fasting GIP was rs17681684 (P = 1.4 × 10–9) in GLP2R, which 
encodes the GLP-2 receptor. rs17681684 was associated with GIP specifically in the fasting state where each 
A allele associated with 5.5% increased GIP levels. No association with 2-hour GIP could be detected. The 
same SNP was nominally associated with decreased 2-hour levels of GLP-1 (P = 5 × 10–4), each allele reducing 
the serum concentration by 3.4%, whereas no effect on fasting levels was found (Table 2). This genetic variant 
causes an amino acid change from an aspartic acid to asparagine (Asp470Asn), but it is not known if  this has 
a functional effect. The amino acid substitution was predicted to be benign (risk score = 0) by the Polyphen-2 
database (20). Because the variant was also nominally associated with decreased glucagon concentrations (P 
= 0.04), we examined GLP2R mRNA expression in human pancreatic islets from cadaver donors. We found 
no significant association with GLP2R mRNA expression (P = 0.05) in human pancreatic islets (Supplemental 
Table 4 and Supplemental Figure 4), and no effect on in vitro insulin secretion (n = 197) measured as stimula-
tory index or glucagon secretion was detectable.
The rs17681684 SNP was also nominally associated with fasting glucose (P = 0.03), and in the DIA-
GRAM database (21), including more than 60,000 individuals, the same allele was associated with increased 
risk of  T2D (P = 8.2 × 10–4). Together, the identified variants in the GIPR and GLP2R loci explained 1.2 % 
of  the fasting GIP variation.
In addition to the GIPR locus, we found 4 loci significantly associated with GIP after OGTT (Table 1).
SLC5A1. The SLC5A1 locus was also associated with 2-hour GIP. Each G allele of  rs17683011 asso-
ciated with 12.2% increased 2-hour GIP levels, and, concomitantly, the corrected insulin response (CIR) 
was increased by 10.0% (P = 0.002). Fasting glucose was slightly lower among the G allele carriers of  
Figure 2. ABO expression in enteroendocrine cells and pancreatic islets. (A) Human colonic sections double immunostained 
for ABO and glucagon-like peptide-1 (GLP-1) as well as ABO and glucose-dependent insulinotropic peptide (GIP), respectively. 
Scale bar: 10 μm. (B) Human pancreatic sections triple immunostained for ABO, insulin, and glucagon. Scale bar: 50 μm.
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rs17683011 (P = 0.03), but no significant association with risk of  T2D was detected in either of  our cohorts 
or in the DIAGRAM database (OR = 0.95, P = 0.12). Neither did we observe any significant association 
with BMI in our cohorts or in the GIANT meta-analysis (P = 0.46) (22).
The G allele of  rs17683011 also associated with 3.5% increased 2-hour glucagon concentration (P = 
7.3 × 10–5). SLC5A1 mRNA was found to be expressed in pancreatic islets from human donors, where its 
expression correlated with expression of  the glucagon (GCG) gene (r2 = 0.31, P = 2 × 10–17). This supports 
previous studies showing expression of  SLC5A1 in α cells (23). In islets, SLC5A1 expression was significant-
ly higher in carriers of  the minor G allele (P = 3.1 × 10–6, Supplemental Table 4 and Supplemental Figure 
4), but the locus was not associated with expression of  the GCG gene (P = 0.55). We did not observe any 
significant association with glucagon secretion in human islets in vitro (P = 0.8); however, this could be due 
to lack of  power, given the limited number of  individuals included in the analysis (n = 95).
ABO. Four SNPs in strong LD (r2 = 0.95-1, D′ = 1), near the ABO gene, were associated with both fast-
ing (P = 6.5 × 10–4) and 2-hour (P = 9.0 × 10–14) GIP concentration but not with GLP-1. The same locus has 
previously been associated with numerous phenotypes, including fasting glucose (24), soluble E-selectin 
(25), ICAM-1 (26), and P-selectin (26). The associated SNPs are in low-to-moderate LD with SNPs in ABO 
that determine blood group (r2 = 0.01––0.51, D′ = 0.19-1). Previous studies have shown that the associated 
SNPs are proxies for the ABO*A101 allele responsible for blood group A1. We estimated the ABO alleles 
of  individuals in the MDC cohort using haplotypes formed of  3 ABO SNPs: rs8176749, rs8176704, and 
rs687289 (26). The estimated ABO allele frequencies corresponded well with their expected frequencies 
(Table 3). The overall P value for the association with 2-hour GIP was 5.1 × 10–8, but after conditioning on 
rs635634, or the A1-haplotype, no remaining association was detected (P > 0.8) (Supplemental Table 5). 
This was further confirmed in the PPP-Botnia cohort (Supplemental Table 6) and meta-analysis (Table 3). 
Immunohistochemistry showed that the ABO protein is expressed in K cells and L cells (Figure 2A).
The ABO locus was also associated with reduced insulin concentrations at 30 minutes (P = 5.7 × 10–4) 
and with increased fasting glucose (P = 0.038) and 2-hour glucose (P = 0.0014). In the MDC cohort, the vari-
ant associated with increased risk of  T2D incidence during a follow-up period of  20–23 years (HR 1.16; CI 
95% 1.01–1.31; P = 0.04). In pancreatic islets, rs507666 was strongly associated with ABO mRNA expression 
(P = 1.0 × 10–7, Supplemental Table 4 and Supplemental Figure 4), but this was mainly due to lower expres-
sion among individuals with the blood group O, and the association was no longer significant after exclusion 
of  these rs687289 homozygous individuals. Immunohistochemistry in human pancreatic islets confirmed 
expression of  ABO protein in β cells (Figure 2B), but we found no association with glucose-stimulated insu-
lin secretion (stimulatory index) in vitro (P = 0.8), in islets from 214 human cadaver donors, suggesting that 
the association with 30-minute insulin could be secondary to the effect on GIP secretion.
The ABO locus was also associated with increased BMI (P = 0.005). The same nominal association has 
been reported by the CHARGE consortium (24), and, in accordance with findings from this consortium, 
the association with BMI was primarily seen in females (P = 0.013). The ABO locus has previously been 
associated with cholesterol uptake and LDL cholesterol concentrations (27). In addition, individuals with 
blood group A express lower levels of  intestinal alkaline phosphatase, which has been shown to affect body 
weight in interaction with high-fat diet in mice (28). We therefore explored whether a similar interactions 
between the locus and dietary habits would be seen in humans. Interestingly, we observed an interaction 
between rs635634 and fat intake (Pinteraction = 0.001), especially saturated fat (Pinteraction = 0.0002) and mono-
unsaturated fat (Pinteraction = 0.004), on BMI (Supplemental Table 7). The positive association between the 
minor allele of  rs635634 and BMI was mainly observed with higher intakes of  fat, while it was associated 
with lower BMI in the tertile with the lowest intake of  saturated (P = 0.003) and monosaturated fat (P = 
0.02) (Supplemental Table 8). Interestingly, a nominally significant association with cholesterol intake was 
also observed (P = 0.02).
F13A1. The T allele of  the rs927332 variant was suggestively associated with increased fasting GIP 
(P = 2.5 × 10–5) and significantly associated with increased 2-hour GIP (P = 4.1 × 10–8) (Table 1) but was 
not associated with GLP-1. The associated SNP is an eQTL (P = 1.6 × 10–6) for F13A1 in tibial arteries 
according to the GTEx database (29), indicating that the locus has a functional effect on this gene and, 
thus, suggesting that this could be the gene responsible for the effect. However, immunohistochemical 
staining showed no specific expression of  F13A1 in the intestinal epithelium. Likewise, we did not 
observe any associated effect on insulin or glucose concentrations at any time point (Table 2) or any 
association with risk of  T2D.
Downloaded from http://insight.jci.org on March 13, 2018.   https://doi.org/10.1172/jci.insight.93306
7insight.jci.org   https://doi.org/10.1172/jci.insight.93306
R E S E A R C H  A R T I C L E
HOXD1. Finally, a rare C allele of  rs150112597 (minor allele frequency = 0.005) was found to be 
associated with 28% reduced 2-hour GIP concentration (P = 1.6 × 10–8). The same C allele was nomi-
nally associated with fasting GIP (P = 0.02), decreased 2-hour glucose (P = 0.002), and BMI (P = 0.034). 
Because of  the low frequency, results for this SNP are not reported in the published large meta-analyses of  
T2D or diabetes-related variables. Immunohistochemical staining of  human intestine showed expression 
of  HOXD1 in GIP-expressing K cells in the jejunum, thus providing some further support for the associa-
tion (Figure 3).
Together, the 5 loci associated with 2-hour GIP explained 2.6% of  the 2-hour GIP variation.
Association of  variants in known T2D loci with hormone concentrations during OGTT. Finally, we did an 
exploratory analysis of  known T2D loci (Supplemental Table 9) (30) to see if  we could find evidence 
that they were associated with glucagon, GIP, and GLP-1 concentrations in our GWAS. Several of  these 
T2D-associated loci showed nominal associations with GIP, GLP-1, and glucagon concentrations, but only 
the GIPR locus was significant after correction for multiple testing (Supplemental Tables 10–12).
Discussion
With the goal to identify new mechanisms for regulation of  hormone secretion in response to oral glucose 
and thereby potential new drug targets, we identified 5 loci that were associated with circulating insulin, 
glucagon, and incretin levels at fasting and 2 hours of  OGTT.
Blood concentration of  incretins is highest at 30–60 minutes after glucose stimulation but remains high 
until approximately 2 hours, at which time it starts to decline; after approximately 4 hours, it is back to 
fasting levels (31). The 2-hour concentrations thus depend on both secretion and clearance, and no definite 
conclusions can therefore be made about which of  these processes is affected by the identified loci. It should 
also be noted that the pancreas and liver are exposed to portal venous concentrations of  incretins and that 
first-pass clearance could alter the peripheral levels of  these hormones.
The heritability/familiality of  incretin secretion during OGTT has previously been estimated to be in 
the 50%–75% range (31, 32), which is markedly higher than the heritability estimates obtained in this study. 
This difference is most likely a consequence of  the GCTA method, which only estimates the proportion of  
variance explained by additive contributions from the genotyped SNPs, not the total heritability. However, 
the accuracy of  the method has also been questioned due to the underlying assumption that may not always 
be true (33, 34). Given this, and the large confidence intervals, the results should be interpreted with caution.
Identifying genes underlying an association is an inherent problem of  GWAS studies, and we can 
therefore not claim that the genes linked to the loci are really causal. Four of  the associated loci are cod-
ing nonsynonymous SNPs; GIPR, SLC5A1, and GLP2R are very strong candidates based on their known 
function, but other genes and/or genetic variants in LD could still be involved in mediating the effect of  
the identified loci.
Figure 3. HOXD1 expression in enteroendocrine cells. (A) Human colonal sections double immunostained for homeobox 
D1 (HOXD1) and glucagon-like peptide-1 (GLP-1) as well as HOXD1 and glucose-dependent insulinotropic peptide (GIP), 
respectively. Scale bar: 10 μm. (B) Triple staining, including DAPI, also shows expression in the nucleus. Scale bar: 10 μm.
Downloaded from http://insight.jci.org on March 13, 2018.   https://doi.org/10.1172/jci.insight.93306
8insight.jci.org   https://doi.org/10.1172/jci.insight.93306
R E S E A R C H  A R T I C L E
SGLT1, the glucose and galactose transporter encoded by SLC5A1, is expressed in the apical cell 
domain of  L and K cells (12), and studies in both rodents and humans have shown that SGLT1 is pivotal 
for intestinal glucose absorption and glucose-dependent incretin secretion (12–16). In this study, we show 
that common genetic variants in the SGLT1 transporter gene have a significant effect on both GIP and 
GLP-1 secretion in humans and as a consequence on insulin response. Interestingly, the same variants are 
associated with increased glucagon secretion. While this could be an effect on the α cell, both the increased 
incretin secretion and the increased mRNA expression in pancreatic islets suggest that the genetic variation 
is involved in increased glucose transport, which would be expected to reduce glucagon secretion. Inclusion 
of  insulin and glucose measures in the regression model did not attenuate the association (β = 0.036 ± 
0.0092, P = 9.0 × 10–5 adjusted, β = 0.035 ± 0.0089, P = 7.3 × 10–5 unadjusted), showing that the increase 
in glucagon secretion was not secondary to increased insulin secretion. Notably, other variants that asso-
ciated with increased GIP concentrations did not associate with glucagon concentrations, suggesting that 
this effect is unique to SGLT1. One possibility is that the variants affect extrapancreatic glucagon secretion, 
since recent data demonstrate that, at least in pancreatectomized individuals, glucagon is secreted from 
extrapancreatic sources in response to oral glucose stimulation, the L cells being the likely source (35).
The minor allele of  the rs635634-tagged locus near ABO has previously been associated with fasting 
glucose levels in a GWAS meta-analysis of  >60.000 individuals (24). Weak nominal associations with 
increased fasting insulin (P = 0.02) and risk of  T2D (P = 0.01) have also been reported (24). In support of  
this, we observed an association with increased fasting and 2-hour glucose as well as decreased 30-minute 
insulin secretion and increased risk of  T2D. Given the much stronger association seen with GIP concen-
tration, and lack of  detectable effect on in vitro glucose-stimulated insulin secretion, it is likely that the 
association with insulin and glucose-related traits is secondary to the effect on GIP secretion. We could also 
replicate the reported nominal association with BMI, including the gender specificity of  the effect. This is 
more difficult to explain by an effect on GIP, as the ABO SNP was associated with increased BMI, whereas 
lower BMI would be the expected effect of  decreased GIP concentrations (36).
The ABO locus has been associated with a large number of  phenotypes (106 phenotypes in GWAS 
Central; http://www.gwascentral.org/phenotypes) including soluble ICAM-1, soluble E-selectin, and sol-
uble P-selectin as well as circulating phytosterols, LDL, and cardiovascular disease (25, 26, 37). However, 
the mechanisms underlying these associations have not been explored. The ABO gene encodes the glycosyl 
transferase that adds the A and B antigenic determinants to the surface of  erythrocytes. The most common 
allele of  the gene is the O allele that has a frame-shift variant, resulting in a nonfunctional protein. The 
product of  the B allele adds a galactose while the A allele enzyme adds an N-acetylgalactosamine to the 
outer galactose residue of  the H-antigen. A1 and A2 mostly produce the same antigen, but the transferase 
activity of  the A1 protein is 38-fold higher than that of  A2, resulting in a much higher cell surface density 
of  A antigen in A1 (38, 39). Since O-linked glycosylation is essential to the function of  many proteins, it 
could theoretically affect GIP levels through a number of  mechanisms. However, the region also contains 
other interesting genes that could mediate the effect, including the carboxyl ester lipase (CEL) gene, which is 
involved in lipid and cholesterol uptake (40).
The ABO locus has consistently been associated with LDL cholesterol levels. The fact that it is also asso-
ciated with phytosterol levels suggests that this association can be caused by an increased uptake of  dietary 
cholesterol or a decreased excretion of  cholesterol from the liver. Interestingly, we found an interaction on 
BMI between the genotype and intake of  saturated fat, a strong marker of  dietary and plasma cholesterol, 
after adjustment for total caloric consumption. In the tertile with the lowest consumption of  saturated fat, 
the ABO locus was associated with lower BMI and the group with the highest intake had an opposite ten-
dency. Whether this really means that people with different blood groups could benefit from different diets 
needs to be examined. Of note, blood group A expresses lower levels of  intestinal alkaline phosphatase, 
which has been shown to affect body weight in interaction with high-fat diet in mice (28). While this interac-
tion is novel and interesting, it requires replication in larger cohorts with comprehensive dietary data.
The rare C allele of  HOXD1 replaces glycine for arginine at position 218 of  the HOXD1 protein, 
a sequence-specific transcription factor involved in the differentiation of  endothelium (41) and limb 
development (42). While HOXD1 has no know function in incretin biology, it is highly expressed in 
the small intestine according to the GTEx database (29). In addition, we found expression of  HOXD1 
protein in K and L cells. The question remains of  whether HOXD1 might affect differentiation of  the 
gut and the enteroendocrine cells.
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GLP-2 is cosecreted with GLP-1 from L cells and has a multitude of  functions in the gastrointestinal 
system, including stimulation of  mucosal growth, glucose transport and glucose transporter 2 expression, 
inhibition of  gastric emptying and gastric acid secretion, and stimulation of  intestinal blood flow (43). The 
GLP-2 receptor is expressed in both the small and large intestine and has been reported in subsets of  human 
enteroendocrine cells (44), but the exact cellular location remains controversial due to low specificity of  
available antibodies. In rat jejunum, expression is mainly seen in enteric neurons and in subepithelial myo-
fibroblasts (45, 46). GLP-2 has been shown to stimulate pancreatic glucagon secretion, which is also sup-
ported here by the observed expression difference and effect on fasting glucagon levels (47). However, this 
could also be an extrapancreatic effect due to the inhibitory effect of  the locus on secretion from the L cells.
While several novel treatment strategies for T2D mimic GLP-1 actions (analogs) or inhibit incretin 
degradation, none is thus far aimed at increasing the secretion of  endogenous incretins. This study provides 
insight into such mechanisms, by which secretion and breakdown of  GIP and GLP-1 are regulated.
Methods
Cohorts
MDC reinvestigation cohort. MDC is a prospective cohort study in which all men and women born between 
1923 and 1950 from the city of  Malmö were invited to participate. A total of  30,447 individuals under-
went a baseline examination between 1991 and 1996 (48). From this cohort, a random sample of  6,103 
individuals screened between 1991 and 1994 were selected to participate in a study aimed at studying car-
diovascular risk factors, the MDC Cardiovascular Cohort (MDC-CC). All individuals from the MDC-CC 
were invited to participate in a reinvestigation starting in 2007 (49). Of  6,103 individuals, 3,734 (age 61–85 
years) accepted and were reexamined between May 2007 and January 2012 and are included in this study. 
Individuals with known diabetes (n = 343) were excluded from the OGTT and were thus not included in 
the analysis of  values after OGTT, while individuals diagnosed with diabetes based on the OGTT were 
included. In total, 527 individuals had T2D. Population characteristics are presented in Supplemental 
Table 13. Diet analyses were performed in 4,892 nondiabetic individuals with diet information. No data 
on hormone concentrations were available in these individuals.
PPP-Botnia cohort. PPP-Botnia is a population-based study in Western Finland started in 2004 to obtain 
accurate estimates of  prevalence and risk factors for T2D, impaired glucose tolerance, impaired fasting 
glucose, and the metabolic syndrome in the adult population and to use this information for prediction 
and prevention of  the disease (50). The participants were randomly recruited from the National Finnish 
Population Registry to represent 6%–7% of  the population in the 18- to 75-year age range. Altogether, 
5,208 individuals participated in the original study and 3,870 (77%) participated in the follow-up study. 
The number of  individuals with diabetes was 307 at the basal visit and 284 at the follow-up. Population 
characteristics are presented in Supplemental Table 14.
Laboratory assays and other measurements
MDC. A 75-g OGTT was performed after an overnight fast in individuals without known diabetes. Blood 
samples were drawn for analysis of  insulin, glucagon, GIP, and GLP-1 concentrations at 0 and 120 min-
utes. Total plasma GLP-1 concentrations (intact GLP-1 and the metabolite GLP-1 9-36 amide) were deter-
mined radioimmunologically using an in-house anti-serum (no. 89390; sensitivity <1 pmol/l) as previously 
described (51). Serum GIP was analyzed using the Human GIP Total ELISA kit EZHGIP-54K (EMD 
Millipore), which has 100% cross reactivity to human GIP(aa 1–42) and GIP(aa 3–42), and range for the 
assay was 9.3–2,250/10.1–2,450 mg/ml. Plasma glucose was analyzed using the Hemocue Glucose Sys-
tem (HemoCue AB). Serum insulin was assayed with an ELISA kit (K6219, Dako) and had no significant 
cross reactivity to proinsulin (range 0.5–206 U/l). Glucagon was measured using a radioimmunoassay 
(GL-32K, EMD Millipore) with less than 2% cross reactivity to oxyntomodulin (range 18.5–400 pg/ml) 
(52). For all assays used for hormone measurements, inter-assay variation was <15% and intra-assay varia-
tion was <10%. BMI was calculated from direct measurements of  weight and height. Dietary habits were 
measured with a modified diet history method (53).
PPP-Botnia. A 75-g OGTT was performed after an overnight fast at both at the basal and follow-up 
visit. Blood samples were drawn at 0, 30, and 120 minutes. Total GIP, 0 and 120 minutes, was measured 
at the basal visit, whereas GLP-1, 0 and 120 minutes, was measured at follow-up. GLP-1 was measured 
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using GLP-1 (total) radioimmunoassay (GLP1T-36HK, EMD Millipore) with high specificity to GLP-1 
(GLP-2, glucagon, and exendin <0.2%). The range was 3–333 pmol/l. Serum insulin was measured by an 
AutoDelfia fluoroimmunometric assay (B080-101, PerkinElmer). Plasma glucose, glucagon, and serum 
GIP concentrations were measured as for MDC. For GLP-1 inter-assay, variation was up to 18%. For all 
other hormone measurements, inter-assay variation was <15% and intra-assay <10%.
Genotyping
Genotyping of  PPP-Botnia and MDC was done at the Broad genotyping facility using the Infinium Omni-
ExpressExome v1.0 B Beadchip array (Illumina) for MDC and the Illumina Infinium Exome v1.0 Bead-
chip for PPP-Botnia.
Genotypes were called using Illumina’s Gencall algorithm in Genomestudio with refinement of  rare vari-
ants with missing calls undertaken using zCall (54). Standard QC filters were applied, in accordance with the 
Exome-chip Quality Control SOP version 5, as developed within the UK exome chip consortium (for more 
information, see the Supplemental Methods). In brief, SNPs were excluded if  they were monomorphic, had a 
low call rate (<99%), or deviated from the Hardy-Weinberg equilibrium (P < 10−4). Samples were excluded if  
they were duplicates, unexpected first/second relatives, sex mismatches, heterozygosity outliers (>3 SD from 
mean), ancestral outliers, or had low call rate (<95%). Mean call rate after QC was >99.5% in both cohorts. 
Cluster plots for all SNPs of  interest were inspected, to ensure accuracy of  genotype calling.
Immunohistochemistry
Tissue handling. Human specimens were fixed in 4% paraformaldehyde, cut in 6-μm sections, and mounted 
on slides. Sections were deparaffinized and then boiled twice for 7 minutes in citrate buffer (0.01 M, pH 
6.0) followed by a 20-minute rinse in running tap water and then 5 minutes in 1× PBS.
Immunohistochemical staining of  pancreatic sections. The following primary antibodies were used: rabbit anti-
ABO (code bs-7589R, dilution 1:500, Bioss), rabbit anti-F13A1 (code HPA001804, dilution 1:500, Sigma- 
Aldrich), goat anti-GIP (code sc-23554, dilution 1:500, Santa Cruz Biotechnology), rabbit anti-GIPR (code 
RbαGIPr551#4, dilution 1:400, provided by Timothy Kieffer, University of British Columbia, Vancouver, Brit-
ish Columbia, Canada), mouse anti-glucagon (code G-2654, dilution 1:9000, Sigma-Aldrich), guinea pig anti-
GLP-1 (code 8707, dilution 1:1280, EuroDiagnostika), mouse anti-HoxD1 (code sc-365853, dilution 1:500, 
Santa Cruz), and guinea pig anti-insulin (code M9003, dilution 1:2500, EuroDiagnostika). Antibodies were 
diluted in PBS containing 0.25% BSA and 0.25% Triton X-100. Human pancreas, colon, and jejunum sections 
(5 μm) were incubated with primary antibodies overnight at 4°C, followed by rinsing in PBS with 0.25% Triton 
X-100 twice for 10 minutes. Thereafter, secondary antibodies (donkey anti-rabbit AMCA [code 711-155-152, 
Jackson Immunoresearch] for ABO; donkey anti-rabbit Cy2 [code 711-225-152, Jackson Immunoresearch] for 
ABO, GIPR, and F13A1; donkey anti-goat Texas Red [code PA1-28662, Thermo Fisher Scientific] for GIP; 
donkey anti-goat Cy2 for GIP [code 705-225-147, Jackson Immunoresearch]; donkey anti-mouse Texas Red 
[code SAB3701112, Sigma-Aldrich] for glucagon; donkey anti-guinea pig [code 706-075-148, Jackson Immu-
noresearch] for GLP-1; donkey anti-mouse Cy2 [code 115-225-166, Jackson Immunoresearch] for HoxD1; 
and donkey anti-guinea pig Cy2 [code 706-225-148, Jackson Immunoresearch] for insulin) were applied for 1 
hour at room temperature. Sections were again rinsed in PBS with 0.25% Triton X-10 and mounted in PBS/
glycerol (1:1). Cy2 and Texas Red were used at a dilution of 1:400, while AMCA was diluted 1:100.
Imaging and morphometry. Immunofluorescence was examined in an epifluorescence microscope (Olym-
pus BX60) with a digital camera (Nikon DS-2Mv).
Human islets
RNA isolation. Isolation of  total RNA was done using the AllPrep DNA/RNA Kit (Qiagen). Quality of  
isolated RNA was assessed by 2100 Bioanalyzer (Agilent Technologies) or 2200 Tapestation (Agilent Tech-
nologies), and quantity was measured on a NanoDrop 1000 (NanoDrop Technologies) or a Qubit 2.0 
Fluorometer (Thermo Fisher Scientific).
Sample preparation for sequencing. 1 μg total RNA of  sufficient quality (RIN > 8) was used for sample 
preparation for sequencing with a TruSeq RNA sample preparation kit (Illumina). The size selection was 
done using Agencourt AMPure XP beads (Beckman Coulter), aiming at a fragment size above 300 bp. The 
resulting libraries were quality controlled on a 2200 Tapestation (Agilent Technologies) before combining 
6 samples into one pool for sequencing on one lane on a flow cell sequenced on a HiSeq 2000 (Illumina).
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Data analysis. The raw data were base called and demultiplexed using CASAVA 1.8.2 (Illumina) before 
alignment to hg19 with STAR. To count the number of  reads aligned to specific transcripts featureCounts 
(http://bioinf.wehi.edu.au/featureCounts/) was used. Raw data were normalized using trimmed mean of  
M values and transformed using voom (limma R-package) before linear modelling.
Insulin secretion. Glucose-stimulated insulin secretion was assessed in a dynamic perfusion system, 
Suprafusion 1000 (BRANDEL). Twenty handpicked islets were perfused with low glucose (1.67 mM) 
for 42 minutes, high glucose (16.7 mM) for 48 minutes, and then low glucose again. Fractions were 
collected at 6-minute intervals, and the secreted insulin was measured by ELISA (Mercodia). The stim-
ulatory index is defined as the ratio between the areas under the curves that were calculated for the low 
and high glucose concentrations.
Glucagon secretion. Human islets were handpicked under a stereo microscope. First, 6–8 groups of  
12 islets were preincubated in a Krebs-Ringer carbonate buffer containing 1 mM glucose in a CO2 incu-
bator for 30 minutes. Next, the islets were incubated in Krebs-Ringer buffer containing 1 or 16.7 mM 
glucose for 60 minutes before an aliquot of  the medium was removed for analysis with RIA (Millipore).
Genotyping. Genotyping was performed using the Illumina Infinium OmniExpressExome-8 v1.0B 
or the Illumina Infinium Exome v1.0 chips. Genotype calling was done with Illumina Genome studio 
software. All samples passed standard genotype QC metrics: sample call rate >98%, only European 
ancestry assessed by principal component analysis comparisons with HapMap populations, gender 
matched, no relatedness, and no genome-wide heterozygosity outliers. SNPs were removed if  the SNP 
call rate <98% and Hardy-Weinberg equilibrium test P < 5.7 × 10–7
Statistics
Association of  SNPs with hormone levels was analyzed using linear regression models and, for pre-
diction of  risk of  T2D in MDC, using Cox regression models. All analyses were adjusted for sex and 
age. Phenotypes with nonnormal distributions (GIP, GLP-1, insulin, glucagon, BMI, and CIR) were 
log transformed before analysis. Individuals who were on antidiabetic medication were excluded. The 
diet-gene interaction analyses in MDC were additionally adjusted for energy intake. The software 
PLINK (55) was used for all genome-wide analyses. A P value of  less than 5 × 10–8 was used to claim 
genome-wide significance. Manhattan and QQ plots are presented in Supplemental Figures 1 and 2. 
The GWAMA software (56) was used to perform meta-analysis of  the phenotype-SNP association 
results from PPP-Botnia (exome chip) and MDC reinvestigation (OmniExpress Exome chip). Fixed-ef-
fects meta-analysis was performed using estimates of  the allelic effect size and standard error. Other 
statistical analysis was done using IBM SPSS Statistics for Windows v.22 or Stata v. 13.1 (StataCorp).
GTEx analysis release v4 (dbGaP accession phs000424.v4.p1) was used for eQTL lookups (29). LD 
was calculated using SNAP v2.2 (57), based on the 1000 Genomes pilot 1 SNP data set.
The heritability estimates of  hormone concentrations during OGTT were calculated using GCTA soft-
ware, which estimates the narrow-sense heritability captured by the genotyped SNPs (9).
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